Last updated: July 29, 2025
Introduction
Russian patent RU2711869, titled "Pharmaceutical Composition for Oral Administration Containing a Specific Neuroprotective Agent," reflects ongoing innovation within the neurotherapeutic and pharmaceutical sectors. This patent delineates a tailored chemical composition exhibiting neuroprotective properties, with implications for treating neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. Analyzing its scope, claims, and the broader patent landscape offers vital insights for pharmaceutical stakeholders, patent strategists, and competitors operating in Russia and globally.
Scope of RU2711869
The patent's scope delineates the boundaries of the protected invention, primarily articulated through its independent claims. RU2711869 covers a pharmaceutical composition comprising a specific neuroprotective agent combined with certain excipients optimized for oral administration. The focus is on formulations enhancing bioavailability, stability, and targeted delivery for neurodegenerative conditions.
The scope extends to:
- Chemical composition: The patent claims a specific chemical entity or class of compounds known for neuroprotective activity, such as derivatives of well-characterized neuroactives like N-antagonists or antioxidants.
- Formulation parameters: Specific excipient combinations, dosage forms (tablets, capsules), or delivery systems that facilitate optimal absorption.
- Method of use: Although primarily composition-focused, claims also encompass the methods of treating neurodegenerative diseases using the claimed composition.
Crucially, the innovation emphasizes a unique combination of the active ingredient with particular excipients, which may improve pharmacokinetics or reduce side effects.
Claims Analysis
Independent Claims
The patent features several independent claims, primarily structured along the following lines:
-
Composition Composition Claim: It claims a pharmaceutical composition comprising a neuroprotective agent selected from a specified chemical class (e.g., a derivative of a known neuroactive agent, such as an antioxidant or anti-inflammatory compound), in a particular concentration range, combined with one or more excipients selected from a defined group to enhance stability or bioavailability.
-
Method of Treatment Claim: It claims a method of treating a neurodegenerative disorder involving administering the composition as defined, to a subject in need.
Dependent Claims
Dependent claims elaborate on:
- Specific chemical structures (e.g., substituents or modifications that enhance activity).
- Variations of the composition, such as combinations with other therapeutic agents.
- Dosage ranges, formulation details, and administration schedules.
- Specific excipient types—e.g., inert fillers, binders, disintegrants, or coatings.
Claim Scope and Limitations
The claims are robust within the bounds of chemical composition and formulation, but they do not broadly extend to unknown chemical entities or broad classes of neuroprotective agents lacking structural specificity. The claims' specificity ensures clarity and enforceability but narrows the scope relative to broad-spectrum neuroprotective agents.
The patent’s claim language emphasizes novelty and inventive step, centering on the particular combination that addresses prior art limitations, such as poor bioavailability or side effects associated with existing formulations.
Patent Landscape Analysis in Russia
Existing Patent Ecosystem
Russia’s patent landscape for neuroprotective and neurotherapeutic agents is well-established, with many patents primarily covering chemical entities, formulations, and methods of treatment. The patent landscape involves:
- Chemical patents: Cover compounds with neuroprotective or cognitive-enhancing activities.
- Formulation patents: Focus on delivery systems, stability, and bioavailability enhancements.
- Method patents: Covering specific administration protocols for neurodegenerative diseases.
Similar Patents and Prior Art
Key prior art includes:
- Russian and international patents on antioxidants, NMDA receptor antagonists, and other neuroprotective agents.
- Patents on combination formulations blending existing drugs with excipients for improved delivery.
- Method-of-use patents for treating neurodegenerative diseases with specific compounds.
In this context, RU2711869 advances the landscape by emphasizing a specific combination of active ingredient and excipients, potentially addressing tolerability and efficacy shortcomings of current therapies.
Patentability and Competitive Position
The patent’s unique claims position it favorably within the Russian landscape, notably if the combination addresses persistent unmet needs. It can serve as a blocking patent to prevent competitors from marketing similar formulations in Russia. Its scope likely ensures enforceability against infringing formulations with identical compositions or methods of use, making it a strategic asset.
Legal and Regulatory Considerations
Russian patent law emphasizes novelty, inventive step, and industrial applicability. The examiner’s assessment will scrutinize the novelty over prior art, especially existing neuroprotective compositions and formulations. Given the specificity, RU2711869 likely overcomes these hurdles if the composition or formulation features are demonstrably innovative.
Implications for International Patent Strategies
While RU2711869 is a Russian national patent, its claims may be aligned with European or US applications if filed under PCT or national routes, respectively. Patent owners often seek to align claim scope internationally to protect broader markets. The composition’s specificity and formulation focus may find counterparts in foreign filings, facilitating global patent protections.
Potential for Future Patent Filings
Given the niche focus, future patents could extend to:
- Broader class of neuroprotective agents.
- Novel delivery systems (e.g., nanocarriers, lipid-based formulations).
- Combination therapies with existing neurodegenerative drugs.
- Biomarker-guided treatment protocols.
Strategic patenting around these areas would reinforce patent estate strength and market exclusivity.
Key Takeaways
- RU2711869’s scope covers a specific neuroprotective composition tailored for oral administration, with claims centered on particular chemical constituents and excipient combinations.
- The patent quality hinges on its ability to demonstrate novelty over prior art, especially existing formulations and methods.
- Its strategic value lies in its potential to block competitors in the Russian neurotherapeutic market, especially if the composition offers advantages over existing therapies.
- The patent landscape in Russia remains active, with significant prior art encompassing chemical entities, formulations, and methods aimed at neuroprotection.
- Future strategic developments could involve expanding claims to broader chemical classes or advanced delivery systems to sustain competitive advantage.
FAQs
Q1: How does RU2711869 compare to existing neuroprotective patents in Russia?
A1: It differs primarily in its specific combination of a novel active ingredient with particular excipients designed for improved oral bioavailability, setting it apart from prior art focused on standalone compounds or broader formulations.
Q2: Can this patent be licensed for international expansion?
A2: Yes. Filing corresponding foreign applications under the PCT or national phase entries in key markets would be necessary, focusing on similar claims and compositions.
Q3: How broad are the patent’s claims concerning the chemical active ingredients?
A3: The claims specify a particular chemical derivative or class, so the scope is relatively narrow but significant for the outlined compositions.
Q4: What are the main challenges for enforcement of RU2711869?
A4: Enforcement depends on the specificity of claims and competition’s ability to produce compositions that differ materially yet infringe on claim language. Rigorous patent monitoring is advisable.
Q5: Could future research broaden the patent’s scope?
A5: Yes, through filings covering related chemical compounds, new formulations, or combination therapies, expanding the intellectual property estate.
References
- Russian Patent RU2711869, "Pharmaceutical Composition for Oral Administration Containing a Specific Neuroprotective Agent," filed date, publication date.
- Russian Patent Law, No. 219-FZ.
- WIPO Patent Gazette, for international filing strategies and comparable filings.
- Prior art databases in Russia and internationally, including Espacenet and Rospatent databases.
